Systemic treatment of advanced non-small cell lung cancer

Anne M. Traynor, Joan H. Schiller

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Lung cancer, a highly lethal malignancy, is the leading cause of cancer-related mortality in the US, accounting for 28% of all deaths related to cancer. Non-small cell lung cancer comprises 80-85% of lung cancer diagnoses and includes the histologies of adenocarcinoma and its subtype bronchoalveolar carcinoma, squamous cell carcinoma and large cell carcinoma. This article reviews the use of cytotoxic chemotherapies and other systemic treatments for patients with advanced (metastatic and/or recurrent) non-small cell lung cancer. Despite great efforts, only minor gains have been made over the past decade in the treatment of advanced non-small cell lung cancer for patients with a good performance status in terms of prolonging survival and improving quality of life. Currently, the standard of treatment is a platinum-based doublet, with the second agent being selected contingent upon the comorbidities of the patient and the toxicity profile of the drug. The focus of clinical research is centered on the application of the use of targeted, molecularly directed therapies, likely used in combination with either cytotoxics and/or other novel targeted agents, in an attempt to improve the therapeutic ratio of systemic treatments for this large population.

Original languageEnglish (US)
Pages (from-to)697-710
Number of pages14
JournalDrugs of Today
Volume40
Issue number8
DOIs
StatePublished - Aug 2004

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Therapeutics
Large Cell Carcinoma
Neoplasms
Platinum
Drug-Related Side Effects and Adverse Reactions
Comorbidity
Squamous Cell Carcinoma
Histology
Adenocarcinoma
Quality of Life
Carcinoma
Drug Therapy
Survival
Mortality
Research
Population

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Systemic treatment of advanced non-small cell lung cancer. / Traynor, Anne M.; Schiller, Joan H.

In: Drugs of Today, Vol. 40, No. 8, 08.2004, p. 697-710.

Research output: Contribution to journalArticle

Traynor, Anne M. ; Schiller, Joan H. / Systemic treatment of advanced non-small cell lung cancer. In: Drugs of Today. 2004 ; Vol. 40, No. 8. pp. 697-710.
@article{4898c5f6100d4810b033dc5898c6dbb3,
title = "Systemic treatment of advanced non-small cell lung cancer",
abstract = "Lung cancer, a highly lethal malignancy, is the leading cause of cancer-related mortality in the US, accounting for 28{\%} of all deaths related to cancer. Non-small cell lung cancer comprises 80-85{\%} of lung cancer diagnoses and includes the histologies of adenocarcinoma and its subtype bronchoalveolar carcinoma, squamous cell carcinoma and large cell carcinoma. This article reviews the use of cytotoxic chemotherapies and other systemic treatments for patients with advanced (metastatic and/or recurrent) non-small cell lung cancer. Despite great efforts, only minor gains have been made over the past decade in the treatment of advanced non-small cell lung cancer for patients with a good performance status in terms of prolonging survival and improving quality of life. Currently, the standard of treatment is a platinum-based doublet, with the second agent being selected contingent upon the comorbidities of the patient and the toxicity profile of the drug. The focus of clinical research is centered on the application of the use of targeted, molecularly directed therapies, likely used in combination with either cytotoxics and/or other novel targeted agents, in an attempt to improve the therapeutic ratio of systemic treatments for this large population.",
author = "Traynor, {Anne M.} and Schiller, {Joan H.}",
year = "2004",
month = "8",
doi = "10.1358/dot.2004.40.8.850472",
language = "English (US)",
volume = "40",
pages = "697--710",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "8",

}

TY - JOUR

T1 - Systemic treatment of advanced non-small cell lung cancer

AU - Traynor, Anne M.

AU - Schiller, Joan H.

PY - 2004/8

Y1 - 2004/8

N2 - Lung cancer, a highly lethal malignancy, is the leading cause of cancer-related mortality in the US, accounting for 28% of all deaths related to cancer. Non-small cell lung cancer comprises 80-85% of lung cancer diagnoses and includes the histologies of adenocarcinoma and its subtype bronchoalveolar carcinoma, squamous cell carcinoma and large cell carcinoma. This article reviews the use of cytotoxic chemotherapies and other systemic treatments for patients with advanced (metastatic and/or recurrent) non-small cell lung cancer. Despite great efforts, only minor gains have been made over the past decade in the treatment of advanced non-small cell lung cancer for patients with a good performance status in terms of prolonging survival and improving quality of life. Currently, the standard of treatment is a platinum-based doublet, with the second agent being selected contingent upon the comorbidities of the patient and the toxicity profile of the drug. The focus of clinical research is centered on the application of the use of targeted, molecularly directed therapies, likely used in combination with either cytotoxics and/or other novel targeted agents, in an attempt to improve the therapeutic ratio of systemic treatments for this large population.

AB - Lung cancer, a highly lethal malignancy, is the leading cause of cancer-related mortality in the US, accounting for 28% of all deaths related to cancer. Non-small cell lung cancer comprises 80-85% of lung cancer diagnoses and includes the histologies of adenocarcinoma and its subtype bronchoalveolar carcinoma, squamous cell carcinoma and large cell carcinoma. This article reviews the use of cytotoxic chemotherapies and other systemic treatments for patients with advanced (metastatic and/or recurrent) non-small cell lung cancer. Despite great efforts, only minor gains have been made over the past decade in the treatment of advanced non-small cell lung cancer for patients with a good performance status in terms of prolonging survival and improving quality of life. Currently, the standard of treatment is a platinum-based doublet, with the second agent being selected contingent upon the comorbidities of the patient and the toxicity profile of the drug. The focus of clinical research is centered on the application of the use of targeted, molecularly directed therapies, likely used in combination with either cytotoxics and/or other novel targeted agents, in an attempt to improve the therapeutic ratio of systemic treatments for this large population.

UR - http://www.scopus.com/inward/record.url?scp=4644343143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644343143&partnerID=8YFLogxK

U2 - 10.1358/dot.2004.40.8.850472

DO - 10.1358/dot.2004.40.8.850472

M3 - Article

C2 - 15510241

AN - SCOPUS:4644343143

VL - 40

SP - 697

EP - 710

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 8

ER -